An integrative ChIP-chip and gene expression profiling to model SMAD regulatory modules

Human Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA.
BMC Systems Biology (Impact Factor: 2.44). 08/2009; 3(1):73. DOI: 10.1186/1752-0509-3-73
Source: PubMed


The TGF-beta/SMAD pathway is part of a broader signaling network in which crosstalk between pathways occurs. While the molecular mechanisms of TGF-beta/SMAD signaling pathway have been studied in detail, the global networks downstream of SMAD remain largely unknown. The regulatory effect of SMAD complex likely depends on transcriptional modules, in which the SMAD binding elements and partner transcription factor binding sites (SMAD modules) are present in specific context.
To address this question and develop a computational model for SMAD modules, we simultaneously performed chromatin immunoprecipitation followed by microarray analysis (ChIP-chip) and mRNA expression profiling to identify TGF-beta/SMAD regulated and synchronously coexpressed gene sets in ovarian surface epithelium. Intersecting the ChIP-chip and gene expression data yielded 150 direct targets, of which 141 were grouped into 3 co-expressed gene sets (sustained up-regulated, transient up-regulated and down-regulated), based on their temporal changes in expression after TGF-beta activation. We developed a data-mining method driven by the Random Forest algorithm to model SMAD transcriptional modules in the target sequences. The predicted SMAD modules contain SMAD binding element and up to 2 of 7 other transcription factor binding sites (E2F, P53, LEF1, ELK1, COUPTF, PAX4 and DR1).
Together, the computational results further the understanding of the interactions between SMAD and other transcription factors at specific target promoters, and provide the basis for more targeted experimental verification of the co-regulatory modules.

Download full-text


Available from: Louise Showe, Sep 30, 2015
1 Follower
53 Reads
  • Source
    • "Chromatin immunoprecipitation (ChIP)-PCR was performed as previously described [34]. In brief, 2 × 106 OSCC cells were cross-linked with 1% formaldehyde and washed with PBS in the presence of protease inhibitors. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background The treatment of oral squamous cell carcinoma (OSCC) following early detection is associated with good outcomes. Therefore, the survival and prognosis of OSCC patients could be hugely improved by identifying reliable biomarkers for the early diagnosis of the disease. Our previous methylation microarray analysis results have suggested that the gene encoding tissue factor pathway inhibitor-2 (TFPI-2) is a potential clinical predictor as well as a key regulator involved in OSCC malignancy.Methods Methylation of the TFPI-2 promoter in oral tissue specimens was evaluated by bisulfite sequencing assay, quantitative methylation-specific PCR, and pyrosequencing assay. The differences in methylation levels among the groups were compared using the Mann¿Whitney U test. The area under the receiver operating characteristic curve (AUROC) was used to evaluate the discrimination ability for detecting OSCC. Cellular TFPI-2 expression was analyzed by quantitative reverse-transcription PCR before and after treatment with 5¿-aza-2¿-deoxycytidine and trichostatin A, to confirm whether TFPI-2 was epigenetically silenced in OSCC cells. We investigated whether TFPI-2 plays a role as a tumor suppressor by establishing TFPI-2-overexpressing OSCC cells and subjecting them to in vitro cellular proliferation, migration, and invasion assays, as well as an in vivo metastasis assay.Results TFPI-2 was hypermethylated in OSCC tissues versus normal oral tissues (P¿<¿0.0001), with AUROC¿=¿0.91, when using a pyrosequencing assay to quantify the methylation level. TFPI-2 silencing in OSCC was regulated by both DNA methylation and chromatin histone modification. Restoration of TFPI-2 counteracted the invasiveness of OSCC by inhibiting the enzymatic activity of matrix metalloproteinase-2, and consequently interfered with OSCC metastasis in vivo.Conclusions Our data suggest strongly that TFPI-2 is a down-regulated tumor suppressor gene in OSCC, probably involving epigenetic silencing mechanisms. The loss of TFPI-2 expression is a key event for oral tumorigenesis, especially in the process of tumor metastasis.
    Journal of Translational Medicine 09/2014; 12(1):237. DOI:10.1186/s12967-014-0237-7 · 3.93 Impact Factor
  • Source
    • "With the exception of the progesterone receptor signature (which utilized the CLAUS PGR POSITIVE MENINGIOMA (Claus et al., 2008) signature from MSigDB-c2, version 3.1), oncogenic signatures were defined using the following gene lists from MSigDB-c6 (Liberzon et al., 2011, version 3.1) for GSEA analysis: TGFB UP.V1 (Padua et al., 2008), MTOR UP.N4.V1 (Wei et al., 2006), P53 DN.V2 (Elkon et al., 2005), and BRCA DN.V1 (Furuta et al., 2006). GSEA (Subramanian et al., 2005, version 2.0) calculated p-values by permutation over phenotypes whenever possible (Anders et al., 2008; Chin et al., 2006; Claus et al., 2008; Elkon et al., 2005; Finak et al., 2008; Huang et al., 2003; Padua et al., 2008; Sartor et al., 2010; Scandura et al., 2004; The Cancer Genome Atlas Network, 2012; Wei et al., 2006), although there were a few datasets with less than 3 replicates for which gene sets had to be permuted instead of phenotypes (Furuta et al., 2006; Qin et al., 2009; Renzoni et al., 2004). For recovery of known perturbations of oncogenic regulators, GSEA results must either show a FWER p-value < 0.25 or a NOM p-value < 0.05, which are the default cut-offs. "
    [Show abstract] [Hide abstract]
    ABSTRACT: BD-Func (BiDirectional FUNCtional enrichment) is an algorithm that calculates functional enrichment by comparing lists of pre-defined genes that are known to be activated versus inhibited in a pathway or by a regulatory molecule. This paper shows that BD-Func can correctly predict cell line alternations and patient characteristics with accuracy comparable to popular algorithms, with a significantly faster run-time. BD-Func can compare scores for individual samples across multiple groups as well as provide predictive statistics and receiver operating characteristic (ROC) plots to quantify the accuracy of the signature associated with a binary phenotypic variable. BD-Func facilitates collaboration and reproducibility by encouraging users to share novel molecular signatures in the BD-Func discussion group, which is where the novel progesterone receptor and LBH589 signatures from this paper can be found. The novel LBH589 signature presented in this paper also serves as a case study showing how a custom signature using cell line data can accurately predict activity in vivo. This software is available to download at
    PeerJ 09/2013; 1(1):e159. DOI:10.7717/peerj.159 · 2.11 Impact Factor
  • Source
    • "Other components in this family, including BMPR2 (FDR q-value = 0.125) and SMAD7 (FDR q-value = 0.223), also showed evidence of modest down-regulation while SMAD1 showed evidence of modest up-regulation (FDR q-value = 0.101). To determine whether the TGFβ pathway might be affected by emphysema pathogenesis, we used seven previously published studies that had examined the effect of TGFβ ligands on gene expression to develop a collection of signatures of TGFβ pathway activation [19-23,30,31]. Genes that exhibited significantly decreased expression with increasing emphysema severity were enriched among genes induced in response to TGFβ treatment in a total of three datasets (FDR <0.05, GSEA). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease consisting of emphysema, small airway obstruction, and/or chronic bronchitis that results in significant loss of lung function over time. Methods In order to gain insights into the molecular pathways underlying progression of emphysema and explore computational strategies for identifying COPD therapeutics, we profiled gene expression in lung tissue samples obtained from regions within the same lung with varying amounts of emphysematous destruction from smokers with COPD (8 regions × 8 lungs = 64 samples). Regional emphysema severity was quantified in each tissue sample using the mean linear intercept (Lm) between alveolar walls from micro-CT scans. Results We identified 127 genes whose expression levels were significantly associated with regional emphysema severity while controlling for gene expression differences between individuals. Genes increasing in expression with increasing emphysematous destruction included those involved in inflammation, such as the B-cell receptor signaling pathway, while genes decreasing in expression were enriched in tissue repair processes, including the transforming growth factor beta (TGFβ) pathway, actin organization, and integrin signaling. We found concordant differential expression of these emphysema severity-associated genes in four cross-sectional studies of COPD. Using the Connectivity Map, we identified GHK as a compound that can reverse the gene-expression signature associated with emphysematous destruction and induce expression patterns consistent with TGFβ pathway activation. Treatment of human fibroblasts with GHK recapitulated TGFβ-induced gene-expression patterns, led to the organization of the actin cytoskeleton, and elevated the expression of integrin β1. Furthermore, addition of GHK or TGFβ restored collagen I contraction and remodeling by fibroblasts derived from COPD lungs compared to fibroblasts from former smokers without COPD. Conclusions These results demonstrate that gene-expression changes associated with regional emphysema severity within an individual's lung can provide insights into emphysema pathogenesis and identify novel therapeutic opportunities for this deadly disease. They also suggest the need for additional studies to examine the mechanisms by which TGFβ and GHK each reverse the gene-expression signature of emphysematous destruction and the effects of this reversal on disease progression.
    Genome Medicine 08/2012; 4(8):67. DOI:10.1186/gm368 · 5.34 Impact Factor
Show more